Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases

A technology for multiple sclerosis and demyelinating diseases, applied in the field of treatment of MS and other demyelinating diseases, can solve the problem that the treatment has not been proved to be effective for humans

Inactive Publication Date: 2007-04-18
AVENTIS PHARMA INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these treatments have proven effective in humans, and some of them require extensive neurosurgical intervention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
  • Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases
  • Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] As used herein, the expression "pharmaceutically acceptable carrier" means a non-toxic solvent, dispersant, excipient, adjuvant or other compound with which the compound of the present invention is mixed to form a pharmaceutical composition, that is, capable of being administered to a patient. dosage form of the substance. An example of such a carrier is a pharmaceutically acceptable oil, which is usually used for parenteral administration.

[0022] The term "pharmaceutically acceptable salt" as used herein means that the salts of the compounds of the present invention can be used in the preparation of medicines. However, other salts may be used in the preparation of the compounds according to the invention and their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of the invention include acid addition salts which can be prepared by mixing a solution of the compounds of the invention with a pharmaceutically acceptable acid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for treating demyelinating diseases in a patient in need thereof by treatment with an effective amount of a PPAR delta agonist is disclosed. Demyelinating diseases that may be effectively treated by this method include but are not limited to multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, Guillian-Barre syndrome and disorders in which myelin forming glial cells are damaged including spinal cord injuries, neuropathies and nerve injury.

Description

field of invention [0001] The present invention relates to the use of PPAR-delta agonists for the treatment of multiple sclerosis (MS) and other demyelinating diseases. The present invention also relates to the use of certain compounds that are selective PPAR-delta agonists for the treatment of MS and other demyelinating diseases. Background of the invention [0002] Peroxisome proliferator-activated receptors (PPARs) comprise a subfamily of the nuclear receptor superfamily. Three closely related isoforms, commonly referred to as PPAR-α, PPAR-γ, and PPAR-δ, have been identified and cloned. Each receptor subtype has a characteristic DNA-binding domain (DBD) and a ligand-binding domain (LBD), both of which are necessary for ligand-activated gene expression. PPAR binds to the retinoid X receptor as a heterodimer. See J. Berger and D. E. Miller, Ann. Rev. Med., 2002, 53, 409-435. [0003] PPAR-delta (also known as PPAR-beta) is expressed in a wide range of mammalian tissues,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61K31/426A61P25/02A61P25/28
CPCA61K31/192A61K31/426A61P25/00A61P25/02A61P25/28A61P43/00A61K2300/00A61K31/185
Inventor K·尚德罗斯J·梅里尔A·明尼克李岚O·霍克瓦刘云
Owner AVENTIS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com